Organigram Global Inc. (OGI) Stock Analysis

Company Overview

Organigram Global Inc. (OGI) is capitalised at $166.50M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 1,139 employees.

The 52-week range on file runs from $0.85 to $2.24. OGI last closed at $1.16 on September 4, 2026. That is −$0.01 (−1.28%) against the previous close. The latest close sits 35.4% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $259.18M. Against the prior fiscal year total of $159.84M, that is a change of +62.15%. The same year closed with a net loss of $24.76M. The reported profit margin is 28.02%. That is 31.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 0.43.

Across the 4 fiscal years on file, revenue moves from $79.16M in 2021 to $259.18M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

OGI trades at a trailing price-to-earnings ratio of 2.69. That is 0.1 times the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 48.13. The price-to-sales ratio is 0.54. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned −28.26%. Across 5 years the annualized return works out at −35.81%. Annualized volatility over the trailing 7 years is 82.55%.

Growth & Income

The record shows no dividend for OGI.

The strongest complete calendar year on file is 2021 at +31.58%; the weakest is 2023 at −59.06%. Of the 6 complete calendar years on file, 3 finished higher. So far in 2026 the price is −31.25%.